Case 16-2004 by Amato, Anthony A. & Oaklander, Anne Louise
Case 16-2004
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Amato, Anthony A., and Anne Louise Oaklander. 2004. “Case
16-2004.” Edited by Richard C. Cabot, Nancy Lee Harris, Jo-Anne
O. Shepard, Sally H. Ebeling, Stacey M. Ellender, and Christine C.
Peters. New England Journal of Medicine 350 (21) (May 20): 2181–
2189. doi:10.1056/nejmcpc049005.
Published Version 10.1056/NEJMcpc049005
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:34625776
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
 n engl j med 
 
350;21
 
www.nejm.org may 
 
20, 2004
 
The
 
 new england journal 
 
of
 
 medicine
 
2181
 
case records 
 
of the
 
 
 
massachusetts general hospital
 
Founded by
 
 Richard C. Cabot
Nancy Lee Harris, 
 
m.d.,
 
 
 
Editor
 
Jo-Anne O. Shepard, 
 
m.d.
 
, 
 
Associate Editor
 
Stacey M. Ellender, 
 
Assistant Editor
 
Sally H. Ebeling, 
 
Assistant Editor
 
Christine C. Peters, 
 
Assistant Editor
 
Case 16-2004: A 76-Year-Old Woman 
with Numbness and Pain in the Feet and Legs
 
Anthony A. Amato, M.D., and Anne Louise Oaklander, M.D., Ph.D.
 
From the Department of Neurology, Divi-
sion of Neuromuscular Medicine, Brig-
ham and Women’s Hospital (A.A.A.); the
Department of Neurology, Harvard Medi-
cal School (A.A.A., A.L.O.); and the Nerve
Injury Unit, Departments of Anesthesia
and Critical Care, and the Departments of
Neurology and Neuropathology, Massa-
chusetts General Hospital (A.L.O.) — all
in Boston.
N Engl J Med 2004;350:2181-9.
 
Copyright © 2004 Massachusetts Medical Society.
 
A 76-year-old woman was referred to the Pain Center of this hospital because of pain
and numbness in her feet and legs. Six years earlier, intermittent numbness had devel-
oped in the toes of her right foot; the numbness slowly spread to both feet and then to
the lower legs. The pain was worse at night and awakened her with a burning sensation
that involved both legs nearly up to the knees and extended at times to the hips. She rated
her pain as 6 on a scale of 1 to 10, with 10 indicating the most intense pain. Additional
symptoms that she reported included “pins and needles” and aching in the legs and
feet. She had had no difficulty walking and no change in bladder or bowel function, al-
though she had experienced a decrease in sensation in the perineal area. She had had
some episodes of facial flushing and sweating, as well as brief light-headedness on oc-
casion (without syncope). Her only other symptoms were dry mouth and constipation.
Thirteen years earlier, a thoracic meningioma found during an evaluation of midtho-
racic back pain and anorexia had been removed; both symptoms resolved after the op-
eration. Four years earlier, a laminectomy to decompress stenosis of the lumbar spine
was performed because of the onset of low back pain; the back pain improved, but the
numbness and burning in the patient’s feet continued to worsen.
One year before her evaluation at this hospital, gadolinium-enhanced magnetic res-
onance imaging (MRI) of the thoracic region disclosed postoperative changes from the
T7 level to the T10 level, with no evidence of any abnormal masses. A central syrinx, 1 to
2 mm in diameter, extended over a length of 2 cm at the T9 level. MRI of the lumbar
spine eight months later revealed mild disk bulges, without disk herniation, a mass, or
nerve-root impingement. There was evidence of a prior partial laminectomy at the L4
and L5 levels. An MRI examination of the cervical spine revealed mild spondylosis at
multiple levels; there was thickening of the ligamentum flavum, which caused mild
spinal stenosis but no deformity of the spinal cord.
An electromyographic examination and nerve-conduction studies of the arms and
legs that had been performed one year previously were normal, as were the results of
motor and sensory conduction studies performed four months before the patient’s eval-
uation at this hospital. Another electromyographic examination revealed minimal ab-
normalities in the intrinsic foot muscles, which raised the possibility of the presence of
a very early stage of axonal polyneuropathy. Somatosensory evoked potentials of the me-
presentation of case
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dian nerves were normal, and those of the tibial
nerves showed latencies at or near the upper limits
of normal.
Laboratory tests performed at other facilities be-
fore the patient came to this hospital had revealed a
normal erythrocyte sedimentation rate, normal re-
sults of serum immunoelectrophoresis, and normal
levels of glucose (as determined by several tests of
fasting blood glucose and two-hour glucose-toler-
ance tests), thyrotropin, glycosylated hemoglobin,
and vitamin B
 
12
 
. Tests for anti–ganglioside GM
 
1
 
,
anti-MAG, and anti-Hu antibodies, and also for se-
rum autoantibodies associated with Sjögren’s syn-
drome, were negative. A radiograph of the chest
showed no abnormalities. 
Localized cancer of the left breast had been treat-
ed three years before with radical mastectomy and
axillary lymph-node dissection, followed by radia-
tion therapy. The patient was married with two adult
children; she was a retired office worker. She did not
use tobacco or alcohol. Two sisters had had diabetes
mellitus, several maternal relatives had had colon
cancer, and paternal relatives had had cardiovascu-
lar disease. The patient’s medications included ga-
bapentin (1200 mg per day), acetaminophen with
codeine (four to six tablets daily), amitriptyline (75
mg nightly), extended-release morphine sulfate
(30 mg daily), as well as hydrochlorothiazide, irbe-
sartan, rabeprazole, vitamin B complex, and docu-
sate sodium. In the past, she had tried topiramate,
topical capsaicin, transdermal fentanyl, and intra-
venously administered immunoglobulin as treat-
ment for her symptoms, but they had not been ef-
fective.
On examination at the Pain Center of this hos-
pital, the patient’s vital signs were normal. She
weighed 80 kg (176 lb). She appeared well. Exami-
nation of the heart, lungs, and abdomen revealed no
abnormalities. There was mild ankle edema. Two
surgical scars were present on the back, and the low
back was tender on palpation. There was good lum-
bar flexion and extension and no pain on perfor-
mance of straight-leg raising. The results of a neu-
rologic examination showed normal mental status
and cranial-nerve function. A motor examination
showed normal tone, bulk, and strength through-
out. Sensory examination showed marked diminu-
tion of the patient’s perception of vibration at the
toes and ankles; the diminution was less evident at
the knees. Sense of joint position was mildly im-
paired at the toes; sensation of cold was reduced at
the feet; perception of pinprick was reduced below
the knees and in the fingers but was intact over the
dorsum of the hand and forearm. There was an area
of allodynia (pain from light touch) and markedly
decreased sensation on the left lateral calf and foot.
The tendon reflexes were ++ at the biceps and tri-
ceps, and + at the knees and ankles. Plantar reflexes
were absent. She could walk on her toes or heels, but
not in tandem. She was extremely unsteady on per-
formance of Romberg’s test.
A diagnostic procedure was performed.
 
Dr. Anthony A. Amato
 
:
 
 There are three goals when
evaluating a patient with a neurologic illness: local-
ize the site of the lesion, identify the cause, and offer
appropriate treatment. A detailed history and neu-
rologic examination can usually localize the site of
the lesion, if not identify the exact cause. Electrodi-
agnostic testing and laboratory testing should be
used as an extension of and not as a substitute for
taking a good history and neurologic examination.
The answers to several questions (Table 1) can nar-
row the differential diagnosis.
This 76-year-old woman had slowly progressive
numbness, paresthesias, and pain, which began in
the feet and ascended to the knees. There was no
weakness, gait instability, poor coordination, radic-
ular pain, bowel or bladder incontinence, urinary
retention, or syncope. Dry mouth and constipation
could be caused by amitriptyline, codeine, or mor-
phine. Neurologic examination showed reduced
perception of pinprick from the knees down and in
the fingers, as well as diminished temperature per-
ception in the feet. Her awareness of vibratory sen-
sation in the toes and ankles was markedly de-
creased. Proprioception was decreased in the toes,
and the patient had a positive response (unsteady
gait with eyes closed) to Romberg’s test. She had
normal muscle tone, muscle strength, and muscle-
stretch reflexes, and plantar responses were absent.
The symptoms as described are those of a pain-
ful sensory neuropathy
 
1
 
 caused by damage to the
A-
 
d
 
 (small myelinated) and polymodal nociceptive
C (unmyelinated) nerve fibers. Dull, burning, poor-
ly localizable pain (protopathic pain) is thought to
be conveyed by polymodal nociceptive C fibers.
Sharp, lancinating, prickly pain (epicritic pain) is
probably mediated through A-
 
d
 
 fibers. The patient’s
reduced sensitivity to pinprick and temperature sen-
sation in the legs suggests neuropathy affecting the
small-diameter nerve fibers.
differential diagnosis
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Reduced vibratory perception limited to the toes
may be seen in patients with small-fiber neuropa-
thies, but the marked impairment and diminished
proprioception reported in this patient, together
with the positive Romberg’s test and normal mus-
cle-stretch reflexes, suggest that these abnormali-
ties are the result of damage to the posterior spinal
cord columns, rather than superimposed damage to
the large, myelinated peripheral-nerve fibers. There
was probably trauma to the posterior columns from
the thoracic meningioma that was excised 13 years
ago. The normal serum levels of vitamin B
 
12
 
 tend
to rule out a diagnosis of a cyanocobalamin defi-
ciency.
The current findings do not suggest a recurrence
of lumbar spinal stenosis, which usually produces
low back and radicular pain, non–length-depen-
dent aching pain, fatigue, and weakness in the legs
that is exacerbated by upright posture and walk-
ing (neurogenic claudication) and relieved by lying
down. I have seen patients whose symptoms did not
improve after lumbosacral laminectomy, because
they actually had painful sensory neuropathy rather
than spinal stenosis.
I suspect the pain and numbness in this patient’s
legs are caused by a small-fiber neuropathy.
 
1-3
 
 Elec-
trodiagnostic testing is essential. Nerve-conduc-
tion studies can be used to assess the function of
large-diameter myelinated peripheral nerves.
 
1
 
 The
studies are useful in determining whether there is
sensory, motor, or sensory and motor involvement
and whether the disease process primarily affects
the axons or the overlying myelin sheaths. De-
creased amplitudes of sensory and compound mus-
cle action potentials are usually associated with
axonopathies; prolonged distal latencies, F-wave
latencies, and slow conduction velocities imply an
abnormality of myelination. The results of standard
nerve-conduction studies are normal in patients
with pure small-fiber neuropathies. In this patient,
the results of these studies were normal, suggesting
a small-fiber neuropathy. In the majority of cases
of small-fiber neuropathy, we cannot identify the
cause.
 
2,3
 
causes of small-fiber neuropathies
 
The causes of chronic, painful sensory neuropathies
include diabetes mellitus, impaired glucose toler-
ance, primary and familial amyloidosis, Sjögren’s
syndrome or sicca complex, vasculitis, human im-
munodeficiency virus (HIV) infection, toxic neurop-
athy due to drugs or other toxins, and rare heredi-
tary neuropathies.
 
2,3
 
 However, these neuropathies
are usually associated with large-fiber sensory in-
volvement and occasionally motor involvement.
There are only a few laboratory tests that are helpful
in evaluating patients with a small-fiber neuropathy.
They include an assessment of the levels of fast-
ing blood sugar and glycosylated hemoglobin, an
oral glucose-tolerance test, serum and urine pro-
tein electropheresis and immunoelectropheresis,
screening for antinuclear antibodies and Sjögren
antibodies (anti-Ro and anti-La or SSA and SSB),
and a measurement of the erythrocyte sedimenta-
tion rate. These tests were all negative or normal in
this patient.
Additional studies were ordered that in my opin-
ion were not necessary and that just added to the
cost. There is no role for tests for so-called antinerve
antibodies (e.g., anti-GM
 
1
 
 ganglioside, anti-MAG,
or antisulfatide antibodies) in patients with painful
sensory neuropathy.
 
4
 
 Anti-GM
 
1
 
 antibodies are as-
sociated with multifocal motor neuropathy and the
Guillain–Barré syndrome, neither of which is a con-
sideration here. Anti-MAG antibodies are found pri-
marily in demyelinating polyneuropathy and IgM
monoclonal gammopathy; they are not associated
with painful small-fiber neuropathies. Antisulfatide
antibodies have very low sensitivity and poor speci-
ficity for the diagnosis of small-fiber neuropathies.
The most common cause of small-fiber neurop-
athy is diabetes mellitus. Our patient had normal
fasting blood glucose and glycosylated hemoglo-
bin levels. Recent studies suggest that the oral glu-
cose-tolerance test should be performed even if
fasting blood glucose and glycosylated hemoglobin
levels are normal in patients who have idiopathic
polyneuropathy, particularly if it is painful.
 
5-7
 
 Im-
paired glucose tolerance (two-hour glucose level,
140 to 200 mg per deciliter) has been reported in up
 
Table 1. Questions to be Addressed in Evaluating Patients with a Neurologic 
Illness.
 
Was the onset of symptoms acute (e.g., over days to weeks), subacute (e.g., 
over a couple of months), or chronic (e.g., over several months or years)?
What is the course of the illness (e.g., monophasic, relapsing–remitting, or 
progressive)?
What was the pattern of involvement (e.g., symmetric or asymmetric) at onset, 
and what is it at present?
What are the associated symptoms and signs (e.g., motor, sensory, or auto-
nomic nervous system involvement)?
What associated medical conditions are present, including medication use 
and history of toxic exposures?
Is this a hereditary or acquired disorder?
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to 36 percent of patients with painful sensory neu-
ropathy and diabetes mellitus (two-hour glucose
level of more than 200 mg per deciliter or fasting
blood glucose level of more than 126 mg per decili-
ter) in up to 39 percent (Table 2). Although the risk
of having both previously undetected diabetes mel-
litus and impaired glucose tolerance is increased in
patients with sensory neuropathy, a causal relation-
ship has not as yet been established.
 
8
 
 The patient
under discussion had normal results on two glu-
cose-tolerance tests, which seems to rule out a di-
agnosis of either impaired glucose tolerance or
diabetes mellitus.
Peripheral neuropathy occurs in 15 to 30 percent
of patients with primary amyloidosis and is the ini-
tial manifestation of the disease in 17 percent of
cases.
 
9
 
 Small nerve fibers are preferentially affected.
Eventually, symmetric weakness and large-fiber sen-
sory loss develop, as does autonomic involvement.
The results of nerve-conduction studies and electro-
myography are typically abnormal. Approximately
90 percent of patients with primary amyloidosis
have a monoclonal protein detected in the serum or
urine. The relatively benign nature of this patient’s
neuropathy, the lack of systemic involvement, and
the absence of a monoclonal gammopathy make a
diagnosis of primary or familial amyloidosis un-
likely.
Sjögren’s syndrome and sicca complex may be
associated with an axonal sensory or sensorimotor
polyneuropathy.
 
10
 
 Although small nerve fibers are
often involved, prolonged isolated small-fiber neu-
ropathy is unusual with either of these disorders.
In the case under discussion, the autoantibodies
that are associated with Sjögren’s syndrome were
absent, making this diagnosis unlikely.
Could this patient have a paraneoplastic neurop-
athy? This syndrome is most common in patients
with small-cell lung carcinoma, but it can also oc-
cur in patients with breast cancer. Neuropathic pain
may be present, but the predominant manifesta-
tions are unsteady gait and poor coordination; the
primary autoimmune attack is directed against the
sensory ganglia, and many patients with a parane-
oplastic neuropathy have limbic encephalitis.
 
11
 
Muscle-stretch reflexes are reduced, as are ampli-
tudes of sensory-nerve action potentials. Antibodies
directed against the Hu antigen are often present in
the serum or cerebrospinal fluid. The absence of
ataxia, the normal muscle-stretch reflexes, the nor-
mal results of the nerve-conduction studies, and the
absence of anti-Hu antibody make paraneoplastic
neuropathy unlikely.
Vasculitis involving the peripheral nervous sys-
tem typically is manifested with multiple mononeu-
ropathies that can overlap and give a picture of a
generalized symmetric polyneuropathy. The neu-
ropathy is painful and usually associated with sen-
sory and motor deficits. Nerve-conduction studies
demonstrate multifocal or generalized axon loss
that affects motor and sensory nerves, and electro-
myography reveals denervation. A few cases of vas-
cular inflammation associated with small-fiber neu-
ropathy have been reported,
 
12
 
 but fibrinoid necrosis
of vessel walls and clinically significant improve-
ment with immunosuppressive agents have not
been demonstrated. It would be unusual for vascu-
litis of this duration to be evident only as a small-
fiber neuropathy.
 
idiopathic small-fiber neuropathy
 
The majority of small-fiber neuropathies remain id-
iopathic despite extensive evaluation. Most patients
present with symptoms when they are between the
ages of 45 and 70 years.
 
13
 
 Approximately 80 percent
of patients report burning pain in the feet. Sharp,
lancinating pain, numbness, or paresthesias occur
in half the patients. The hands often become affect-
ed over time. Symptoms restricted to the upper
limbs and cranial-nerve involvement are exception-
al. Reduced sensitivity to pinprick or temperature
sensation is almost always present. Vibratory per-
ception in the toes is reduced in more than 40 per-
cent of patients, but this sensation is usually nor-
mal in the ankles. Less than 15 percent of patients
have impaired proprioception. Autonomic impair-
ment (dry eyes or mouth, facial flushing, abnormal
sweating, impotence, incontinence, constipation,
or diarrhea) is often seen.
 
14
 
 The results of examina-
tions of motor reflexes and deep-tendon reflexes are
usually normal.
 
*The number cited includes only patients with painful sensory neuropathy.
 
Table 2. Glucose Tolerance in Patients with Small-Fiber Neuropathy.
Reference Patients
Mean Age
(Range)
Abnormal
Glucose
Metabolism
Impaired
Glucose
Tolerance
Diabetes
Mellitus
 
no. yr no. (%)
 
Singleton et al., 2001
 
5
 
33* 64 (44–92) 20 (61) 7 (21) 13 (39)
Novella et al., 2001
 
6
 
28* 64 (41–82) 18 (64) 10 (36) 8 (29)
Sumner et al., 2003
 
7
 
73 61 (44–91) 41 (56) 26 (36) 15 (21)
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What tests could confirm the diagnosis of small-
fiber neuropathy? Quantitative sensory testing of
the thresholds of heat, pain, and cold perception is
used to assess small-fiber function.
 
15
 
 Abnormal
results of quantitative sensory testing have been re-
ported in 60 to 85 percent of patients with predom-
inantly painful sensory neuropathy.
 
3,16
 
 However,
such testing depends on the attention and cooper-
ation of the patients; moreover, it cannot differen-
tiate between simulated sensory loss and sensory
neuropathy, and has relatively low sensitivity and
specificity.
 
17
 
 Another test may be useful. Since the
peripheral autonomic nervous system is often af-
fected in small-fiber neuropathies, the function of
sweat glands innervated by small nerve fibers can be
impaired.
 
18
 
 The quantitative sudomotor axon reflex
test (QSART) is thus highly specific and relatively
sensitive for small-fiber damage, with 59 to 80 per-
cent of patients with neuropathies having abnormal
results.
 
14,16
 
Quantitation of intraepidermal nerve-fiber den-
sity as measured in skin-biopsy specimens identi-
fies an additional 10 percent of patients with small-
fiber neuropathies beyond the percentage identified
with QSART.
 
1
 
 Reduced intraepidermal nerve-fiber
density is present in 50 to 88 percent of patients
with sensory neuropathy.
 
3,19
 
 A sural-nerve biopsy
can be performed, but I would recommend against
it in cases such as that under discussion. Nerve biop-
sies are invasive, associated with permanent sensory
loss in the area supplied by the nerve, and frequently
complicated by increased neuropathic pain. Finally,
they can confirm the presence of small-fiber neu-
ropathy but do not identify the cause.
In summary, I believe the patient has a painful
small-fiber neuropathy that is probably idiopathic.
The quantitative sudomotor axon reflex test or a skin
biopsy could be performed to confirm the diagno-
sis but neither is likely to help us further delineate
the cause.
 
Dr. Nancy Lee Harris 
 
(Pathology): Dr. Lawrence
Hayward followed this patient before and after
her evaluation at Massachusetts General Hospi-
tal. Would you give us your impressions?
 
Dr. Lawrence J. Hayward 
 
(Neurology, University of
Massachusetts Medical Center, Worcester): I first
saw this patient two years ago for disabling pain.
She had already had much of the workup done, in-
cluding the antibody panels. Before the electrodi-
agnostic studies, my initial clinical impression was
that she had a progressive, mixed sensory neurop-
athy. However, the normal results of the nerve-con-
duction studies indicated that this was a predom-
inantly small-fiber neuropathy, perhaps with a
myelopathic component to explain the loss of vi-
bratory perception. The patient was severely debili-
tated by pain and had some additional autonomic
symptoms, so we considered further diagnostic pro-
cedures.
Idiopathic small-fiber neuropathy.
Idiopathic small-fiber neuropathy.
 
Dr. Anne Louise Oaklander:
 
 A left-sided sural-nerve bi-
opsy was performed at the referring institution.
The overall density and appearance of myelinated
fibers in the specimen were normal. A few perineur-
ial blood vessels had focal perivascular mononu-
clear-cell infiltrates that extended through the vessel
wall (Fig. 1A). There was no vasculitis, fibrinoid ne-
crosis, or amyloid deposition. Electron-microscop-
ical examination showed normal axons, myelin, and
Schwann cells, with a few onion-bulb profiles. Emp-
ty, apposed Schwann-cell processes consistent with
degeneration of unmyelinated axons were numer-
ous (Fig. 1B). Neither morphometric analysis nor
teased-fiber preparations were performed.
On initial evaluation at this hospital, two punch-
biopsy specimens were taken from the skin of the
patient’s right lower leg, 10 cm above the lateral
malleolus. Scattered perivascular mononuclear in-
filtrates were present on routine histologic exami-
nation (Fig. 2A). There was no evidence of amyloid.
Staining with a monoclonal antibody to the panax-
onal marker anti–protein gene product 9.5 (anti-
PGP 9.5 antibody) revealed axonal swellings in
some fibers that are consistent with early degener-
ation (Fig. 2B).
 
20
 
 Morphometric analysis revealed
358 neurites per square millimeter of epidermis,
which is 42 percent greater than normal for some-
one the patient’s age (median, 205). Eleven months
later, additional skin-biopsy specimens were ob-
tained 2 cm proximal to the previous biopsy site.
The axonal morphology was again abnormal, and
there was a 61 percent reduction in axonal density,
to 189 neurites per square millimeter, 32 percent
clinical diagnosis
dr.  anthony a.  amato’s  
diagnosis
pathological discussion
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below normal for her age (Fig. 2C). In summary,
specimens from both the sural-nerve and skin bi-
opsies revealed predominantly small-fiber sensory
neuropathy and perivascular lymphocytic infiltrates
of unclear significance, with no evidence of amyloid
deposition or vasculitis.
A sural-nerve biopsy is the traditional method
for pathological evaluation of peripheral neuropa-
thy. It permits comprehensive evaluation of all cell
types, as well as detailed morphometric analysis of
the densities of different-sized axons and of myeli-
nation. The sural nerve is purely sensory and can be
removed without producing weakness; however,
most patients experience distal sensory loss or dys-
function.
 
21 
 
The procedure requires anesthesia and
surgery and is thus expensive. It cannot be repeated
to monitor the progression of disease or the effects
of treatment.
These drawbacks spurred development of a less
invasive alternative: punch biopsies of the skin, with
the specimens immunolabeled to reveal nerve end-
ings. Anti-PGP 9.5 antibody labels ubiquitin hydro-
lase, a lysosomal enzyme
 
22
 
 that is present in all neu-
rons.
 
23
 
 Localization has been verified by electron
microscopy,
 
24
 
 and the methods have been validated
for the study of small-fiber sensory neuropathies
(due to diabetes, HIV, or unknown causes).
 
25
 
 The
epidermis contains the terminals of unmyelinated
C and A-
 
d
 
 nociceptive axons that terminate individ-
ually and that can be quantitated. Even in patients
with normal neurite density, abnormal branching
patterns and axonal swellings suggest early small-
fiber neuropathies.
 
20
 
 The nociceptive axons best
studied with the use of skin-biopsy specimens are
precisely those not captured by electromyographic
and nerve-conduction studies, so these two meth-
ods of analyzing peripheral nerves are complemen-
tary.
 
19
 
 As in this patient, skin biopsies can be repeat-
ed to follow the progression of the disease.
The best management of painful neuropathies con-
sists of treating the underlying causes, but these
are identified in only a minority of cases. Neurosur-
gical decompression is not often helpful, and alter-
native medical treatments are largely ineffective.
 
26
 
Thus, symptomatic pain relief is often the only op-
tion. Four classes of medication have documented
efficacy against painful neuropathy: tricyclic anti-
depressant agents, antiepileptic agents, topical lo-
cal anesthetic agents, and opioid agents. If these
fail, immunosuppression may be appropriate in
selected patients. Many other treatments are pre-
scribed without evidence of efficacy. There are no
clinical trials specifically of treatment for idiopath-
ic painful neuropathy, so conclusions are extrapo-
lated from therapeutic trials involving neuropathy
associated with diabetes or HIV. 
Tricyclic antidepressants are a useful initial step
and were prescribed for this patient.
 
27
 
 Potentiation
of noradrenergic neurotransmission appears to be
their major effect, but they have other actions, in-
discussion of management
 
Figure 1. Specimen from a Sural-Nerve Biopsy.
 
The nerve is morphologically normal on light microsco-
py (Panel A). There is a focal perivascular lymphocytic 
infiltrate, and in one small perineurial vessel (arrow) 
the infiltrate extends through the wall (hematoxylin and 
eosin, ¬125). There is no necrosis or other evidence of 
vasculitis or intraneural inflammation. An electron mi-
crograph (Panel B) shows empty Schwann-cell processes 
(arrows) that are consistent with the loss of small, unmy-
elinated fibers (¬8000). (Photographs courtesy of Drs. 
Lawrence Hayward and Thomas Smith, University of 
Massachusetts Medical School, Worcester.)
A
B
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cluding sodium-channel blockade. Desipramine,
nortriptyline, and amitriptyline are agents in this
class, are all available in generic form, and have doc-
umented efficacy.
 
28
 
 Selective serotonin-reuptake in-
hibitors are not effective in diabetic neuropathy; two
newer antidepressants, venlafaxine and bupropion,
have been reported to be effective, but there has
been only one study of each to date.
 
29,30
 
Gabapentin, an anticonvulsant agent, is now
perhaps the most commonly prescribed medica-
tion for painful neuropathies.
 
31
 
 Its efficacy is com-
parable to that of tricyclic antidepressants, but it has
fewer side effects. This patient obtained some re-
lief from gabapentin. Other anticonvulsants, includ-
ing carbamazepine, oxcarbazepine, and lamotri-
gine, may be effective.
 
32-34
 
 
Topical local anesthetics, including lidocaine
patches, appear to be efficacious and are without
systemic effects.
 
35
 
 Topical capsaicin, which is avail-
able without prescription, produces degeneration
of nociceptive axon terminals.
 
36
 
 It is poorly tolerat-
ed because it causes a burning sensation, and it is
relatively ineffective, as it was in this patient.
 
27
 
Opioid agents have been shown to be reason-
ably efficacious and safe.
 
37
 
 The risk of addiction is
low when there is a clear indication for use and when
the patient has no history of substance abuse. Most
patients are best treated with long-lasting forms
taken at regular intervals. If the pain worsens at
night, as is characteristic of neuropathy, bedtime-
only use is an option. Methadone is a good option
because of its low cost; its activity at the 
 
N
 
-methyl-
 
d
 
-aspartate receptor may potentiate its analgesic
effect.
 
37
 
 Initial adverse effects of opioids, such as
nausea and drowsiness, usually improve rapidly af-
ter initiation, but constipation may persist and re-
quire long-term treatment. This patient reported
only moderate relief from sustained-release mor-
phine, at a dose of 30 mg four times daily, and re-
quested an increase in the dose.
 
Figure 2. Specimens from Skin-Punch Biopsies. 
 
A specimen obtained at the time of the patient’s first evaluation at this hospital (Panel A) shows a focal perivascular 
lymphocytic infiltrate (hematoxylin and eosin, ¬125). A section immunolabeled against protein gene product 9.5 to re-
veal neural processes or axons (thick arrows) (Panel B) shows an epidermal neurite with axonal swellings, which are ab-
normal (thin arrow). The density of nerve fibers is greater than normal (immunoperoxidase, ¬500). A specimen obtained 
11 months later (Panel C) shows marked reduction in neurite density and axonal swelling (arrow) in a remaining neurite 
(¬300).
A B
C
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My recommendation was to consider switching
from amitriptyline to either nortriptyline or desip-
ramine, because they have equal efficacy without
additional side effects, and to continue morphine
and gabapentin at the same dosage. Topical lido-
caine patches should be considered.
 
Dr. Harris:
 
 How does the loss of nociceptive fi-
bers produce pain?
 
Dr. Oaklander:
 
 There is an assumption that the
mechanisms of neuropathic pain are similar to the
mechanisms of inflammatory pain, namely an in-
crease in electrical activity of the subgroup of neu-
rons that is nociceptive. In fact, the loss of nocicep-
tive fibers is one of the major pathologic hallmarks
of neuropathic pain conditions, such as postherpet-
ic neuralgia. There are other situations in which
the reduction of normal sensory input results in
increased central activity and sensory perception;
these include tinnitus after hearing loss and phan-
tom pain after the amputation of a limb.
 
Dr. Harris:
 
 Dr. Hayward, can you give us follow-
up on this patient?
 
Dr. Hayward:
 
 Because she was obese and had a
family history of diabetes, the patient was advised
to follow a diet, and she has lost 20 pounds over the
past year. The numbness has slowly begun to in-
volve her hands and forearms, but her strength has
been preserved. She has had fewer side effects after
switching from amitriptyline to nortriptyline, and
she is trying a topical lidocaine patch. We are con-
sidering a trial of tramadol, a mixed opioid and
monoaminergic agent.
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 Serial glucose-tolerance
testing, performed because of the family history of
diabetes, recently showed a fasting blood glucose
level of 97 mg per deciliter and a two-hour post-
challenge glucose level of 216 mg per deciliter,
suggesting a new diagnosis of diabetes.
 
Dr. Amato:
 
 Although we cannot be sure in this
case that an abnormality of glucose metabolism
that became evident seven years after the onset of
symptoms is the cause of her neuropathy, one has
to be open to the possibility. In patients with small-
fiber neuropathy in whom diabetes mellitus or im-
paired glucose tolerance is detected, the duration of
neuropathic symptoms before the diagnosis rang-
es from 3 to 240 months (median, 54).
 
5-7
 
 These data
suggest that one can have diabetic neuropathy in
the absence of long-standing diabetes. Although
we do not know the natural history of impaired glu-
cose tolerance or the effect of improved glycemic
control on the neuropathy, rigorous glycemic con-
trol reduces the incidence of neuropathy in patients
with known diabetes mellitus.
 
39
 
 Even if this pa-
tient’s neuropathy is unrelated to the newly diag-
nosed diabetes, improved glycemic control may pre-
vent or slow further deterioration resulting from
superimposed diabetic neuropathy.
Small-fiber neuropathy.
 
Presented at the Neurology Grand Rounds, Massachusetts Gen-
eral Hospital, May 1, 2003.
anatomical diagnosis
 
references
 
1.
 
Mendell JR, Sahenk Z. Painful sensory
neuropathy. N Engl J Med 2003;348:1243-55.
 
2.
 
Gorson KC, Ropper AH. Idiopathic dis-
tal sensory small fiber neuropathy. Acta
Neurol Scand 1995;92:376-82.
 
3.
 
Holland NR, Crawford TO, Hauer P,
Cornblath DR, Griffin JW, McArthur JC.
Small-fiber sensory neuropathies: clinical
course and neuropathology of idiopathic
cases. Ann Neurol 1998;44:47-59.
 
4.
 
Wolfe GI, El-Feky WH, Katz JS, Bryan
WW, Wians FH Jr, Barohn RJ. Antibody pan-
els in idiopathic polyneuropathy and motor
neuron disease. Muscle Nerve 1997;20:
1275-83.
 
5.
 
Singleton JR, Smith AG, Bromberg MB.
Painful sensory polyneuropathy associated
with impaired glucose tolerance. Muscle
Nerve 2001;24:1225-8.
 
6.
 
Novella SP, Inzucchi SE, Goldstein JM.
The frequency of undiagnosed diabetes and
impaired glucose tolerance in patients with
idiopathic sensory neuropathy. Muscle Nerve
2001;24:1229-31.
 
7.
 
Sumner CJ, Sheth S, Griffin JW, Corn-
blath DR, Polydefkis M. The spectrum of
neuropathy in diabetes and impaired glu-
cose tolerance. Neurology 2003;60:108-11.
 
8.
 
Russell JW, Feldman EL. Impaired glu-
cose tolerance — does it cause neuropathy?
Muscle Nerve 2001;24:1109-12.
 
9.
 
Kelly JJ Jr, Kyle RA, O’Brien PC, Dyck PJ.
The natural history of peripheral neuropa-
thy in primary systemic amyloidosis. Ann
Neurol 1979;6:1-7.
 
10.
 
Grant IA, Hunder GG, Homburger HA,
Dyck PJ. Peripheral neuropathy associated
with sicca complex. Neurology 1997;48:
855-62.
 
11.
 
Case Records of the Massachusetts
General Hospital (Case 38-2001). N Engl J
Med 2001;345:1758-65.
 
12.
 
Lacomis D, Guiliani MJ, Steen V, Powell
HC. Small fiber neuropathy and vasculitis.
Arthritis Rheum 1997;40:1173-7.
 
13.
 
Notermans NC, Wokke JHJ, Franssen
H, et al. Chronic idiopathic polyneuropathy
presenting in middle or old age: a clinical
and electrophysiological study of 75 pa-
tients. J Neurol Neurosurg Psychiatry 1993;
56:1066-71.
 
14.
 
Novak V, Freimer ML, Kissel JT, et al.
Autonomic impairment in painful neuropa-
thy. Neurology 2001;56:861-8.
 
15.
 
Dyck PJ, O’Brien PC. Quantitative sen-
sation testing in epidemiological and thera-
peutic studies of peripheral neuropathy.
Muscle Nerve 1999;22:659-62.
 
16.
 
Tobin K, Guiliani MJ, Lacomis D. Com-
parison of different modalities for detection
of small-fiber neuropathy. Clin Neurophysi-
ol 1999;110:1909-12.
 
17.
 
Freeman R, Chase KP, Risk MR. Quanti-
tative sensory testing cannot differentiate
simulated sensory loss from sensory neu-
ropathy. Neurology 2003;60:465-70.
 
18.
 
Stewart JD, Low PA, Fealy RD. Distal
small fiber neuropathy: results of tests of
sweating and autonomic cardiovascular re-
flexes. Muscle Nerve 1992;15:661-5.
 
19.
 
Herrman DN, Griffin JW, Hauer P,
Cornblath DR, McArthur JC. Intraepidermal
Downloaded from www.nejm.org at MASS GENERAL HOSP on May 26, 2004.
Copyright © 2004 Massachusetts Medical Society. All rights reserved.
 n engl j med 
 
350;21
 
www.nejm.org may 
 
20, 2004
 
case records of the massachusetts general hospital
 
2189
 
nerve fiber density and sural nerve mor-
phometry in peripheral neuropathies. Neu-
rology 1999;53:1634-40.
 
20.
 
Dahlin LB, Eriksson KF, Sundkvist G.
Persistent postoperative complaints after
whole sural nerve biopsies in diabetic and
non-diabetic subjects. Diabet Med 1997;14:
353-6.
 
21.
 
Thompson RJ, Doran JF, Jackson P,
Dhillon AP, Rode J. PGP 9.5 — a new marker
for vertebrate neurons and neuroendocrine
cells. Brain Res 1983;278:224-8.
 
22.
 
Dalsgaard CJ, Rydh M, Haegerstrand A.
Cutaneous innervation in man visualized
with protein gene product 9.5 (PGP 9.5) an-
tibodies. Histochemistry 1989;92:385-90.
 
23. Hilliges M, Wang L, Johansson O. Ultra-
structural evidence for nerve fibers within all
vital layers of the human epidermis. J Invest
Dermatol 1995;104:134-7.
24. Kennedy WR, Wendelschafer-Crabb G,
Johnson T. Quantitation of epidermal
nerves in diabetic neuropathy. Neurology
1996;47:1042-8.
25. Lauria G, Morbin M, Lombardi R, et al.
Axonal swellings predict the degeneration
of epidermal nerve fibers in painful neurop-
athies. Neurology 2003;61:631-6.
26. Shlay JC, Chaloner K, Max MB, et al.
Acupuncture and amitriptyline for pain due
to HIV-related peripheral neuropathy: a ran-
domized controlled trial. JAMA 1998;280:
1590-5.
27. Sindrup SH, Jensen TS. Efficacy of phar-
macological treatments of neuropathic
pain: an update and effect related to mecha-
nism of drug action. Pain 1999;83:389-400.
28. Max MB, Lynch SA, Muir J, Shoaf SE,
Smoller B, Dubner R. Effects of desipra-
mine, amitriptyline, and fluoxetine on pain
in diabetic neuropathy. N Engl J Med 1992;
326:1250-6.
29. Davis JL, Smith RL. Painful peripheral
diabetic neuropathy treated with venlafaxine
HCl extended release capsules. Diabetes
Care 1999;22:1909-10.
30. Semenchuk MR, Sherman S, Davis B.
Double-blind, randomized trial of bupropi-
on SR for the treatment of neuropathic pain.
Neurology 2001;57:1583-8.
31. Backonja M, Beydoun A, Edwards KR, et
al. Gabapentin for the symptomatic treat-
ment of painful neuropathy in patients with
diabetes mellitus: a randomized controlled
trial. JAMA 1998;280:1831-6.
32. Rull JA, Quibrera R, Gonzalez-Millan H,
Lozano Castaneda O. Symptomatic treat-
ment of peripheral diabetic neuropathy with
carbamazepine (Tegretol): double blind
crossover trial. Diabetologia 1969;5:215-8.
33. Nascimento O, Freitas M, Lacerda G,
Quintanilha G, Naylor F. Encouraging early
results of oxcarbazepine in newly diagnosed
painful peripheral neuropathies. In: Poster
abstracts of the 22nd APS Annual Scientific
Meeting, Chicago, March 20–23, 2003.
Glenview, Ill.: American Pain Society, 2003.
abstract.
34. Simpson DM, Olney R, McArthur JC,
Khan A, Godbold J, Ebel-Frommer K. A pla-
cebo-controlled trial of lamotrigine for
painful HIV-associated neuropathy. Neurol-
ogy 2000;54:2115-9.
35. Barbano RL, Herrmann DN, Galer BS,
et al. Effectiveness of the lidocaine patch 5%
in idiopathic sensory polyneuropathy. In:
Poster abstracts of the Sixth Annual Interna-
tional Conference on the Mechanisms and
Treatment of Neuropathic Pain, San Fran-
cisco, September 18–20, 2003:2. abstract.
36. Simone DA, Nolano M, Johnson T,
Wendelschafer-Crabb G, Kennedy WR. In-
tradermal injection of capsaicin in humans
produces degeneration and subsequent
reinnervation of epidermal nerve fibers: cor-
relation with sensory function. J Neurosci
1998;18:8947-59.
37. Ballantyne JC, Mao J. Opioid therapy for
chronic pain. N Engl J Med 2003;349:1943-
53.
38. Harati Y, Gooch C, Swenson M, et al.
Double-blind randomized trial of tramadol
for the treatment of the pain of diabetic neu-
ropathy. Neurology 1998;50:1842-6.
39. The Diabetes Control and Complica-
tions Trial Research Group. The effect of
intensive treatment of diabetes on the de-
velopment and progression of long-term
complications in insulin-dependent diabe-
tes mellitus. N Engl J Med 1993;329:977-
86.
Copyright © 2004 Massachusetts Medical Society.
35-millimeter slides for the case records
Any reader of  the Journal who uses the Case Records of  the Massachusetts General Hospital as a medical teaching 
exercise or reference material is eligible to receive 35-mm slides, with identifying legends, of the pertinent x-ray films, 
electrocardiograms, gross specimens, and photomicrographs of each case. The slides are 2 in. by 2 in., for use with a 
standard 35-mm projector. These slides, which illustrate the current cases in the Journal, are mailed from the Department 
of Pathology to correspond to the week of publication and may be retained by the subscriber. Each year approximately 
250 slides from 40 cases are sent to each subscriber. The cost of the subscription is $450 per year. Application forms for 
the current subscription year, which began in January, may be obtained from Lantern Slides Service, Department of  
Pathology, Massachusetts General Hospital, Boston, MA 02114 (telephone 617-726-2974). 
Slides from individual cases may be obtained at a cost of $35 per case.
Downloaded from www.nejm.org at MASS GENERAL HOSP on May 26, 2004.
Copyright © 2004 Massachusetts Medical Society. All rights reserved.
